Press release
Age-related Macular Degeneration (AMD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Opthea, Kodiak Sciences, Regenxbio, Alexion, AstraZeneca, Allegro, Apellis, Iveric Bio
"Age-related Macular Degeneration (AMD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Age-related Macular Degeneration Therapeutics Market.
The report provides a detailed description of the Age-related Macular Degeneration drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Age-related Macular Degeneration Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Age-related Macular Degeneration (AMD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Age-related Macular Degeneration therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Age-related Macular Degeneration treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Age-related Macular Degeneration drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Age-related Macular Degeneration treatment market.
Learn More about the Clinical and Commercial Development Activities in the Age-related Macular Degeneration Therapeutics Domain @
https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Age-related Macular Degeneration (AMD) Therapeutics Analysis
Age-related Macular Degeneration (AMD) Therapeutics Analysis reveals a multifaceted landscape marked by innovative research and a spectrum of treatment modalities aimed at addressing this prevalent cause of vision loss. Therapies for AMD primarily bifurcate into two categories: anti-vascular endothelial growth factor (anti-VEGF) drugs and emerging treatments targeting alternative pathways involved in AMD progression. Anti-VEGF agents like ranibizumab, aflibercept, and bevacizumab have been pivotal in managing neovascular or "wet" AMD by inhibiting abnormal blood vessel growth in the retina.
However, challenges persist, including the need for frequent injections and resistance to treatment in some patients. Researchers are exploring diverse approaches, such as sustained-release drug delivery systems, gene therapies, complement inhibitors, and regenerative medicine, aiming to develop longer-lasting treatments and address different subtypes of AMD. The landscape is also witnessing a shift towards personalized medicine, leveraging genetic insights to tailor therapies based on individual patient characteristics. Clinical trials are investigating novel targets and combination therapies, offering promise for more effective, targeted, and durable treatments that may revolutionize the management of AMD and potentially prevent vision loss in affected individuals.
Age-related Macular Degeneration Companies in the Therapeutics Market Include:
Alkahest Inc, Alexion Pharmaceuticals, Allegro Ophthalmics, Alkeus Pharmaceuticals, Apellis Pharmaceuticals, AstraZeneca, Annexon Biosciences, Clearside Biomedical, CellCure Neurosciences, Evergreen Therapeutics, Gyroscope Therapeutics, Gemini Therapeutics, Graybug Vision, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences Inc., Luxa Biotechnology, NGM Biopharmaceuticals, Novartis, Opthea Limited, Outlook Therapeutics, Inc., PanOptica, REGENXBIO, Regeneron Pharmaceuticals, Regenerative Patch Technologies, Ribomic USA Inc., Roche, Stealth BioTherapeutics, Unity Biotechnology Inc., and numerous other companies collectively contributing to the development of new therapies for the treatment of Age-related Macular Degeneration.
Emerging and Marketed Age-related Macular Degeneration (AMD) Therapies Covered in the Report Include:
• OPT-302: Opthea Limited
• KSI-301: Kodiak Sciences Inc.
• RGX-314: Regenxbio
• Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
• EG-301: Evergreen Therapeutics
• Pegcetacoplan: Apellis Pharmaceuticals
• Zimura: Iveric bio
• Luminate: Allegro Ophthalmics
• NGM621: NGM Biopharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• OpRegen: CellCure Neurosciences/Lineage Cell Therapeutics/Roche
• GT005: Gyroscope Therapeutic
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Age-related Macular Degeneration Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Age-related Macular Degeneration Current Treatment Patterns
4. Age-related Macular Degeneration - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Age-related Macular Degeneration Late-Stage Products (Phase-III)
7. Age-related Macular Degeneration Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Age-related Macular Degeneration Discontinued Products
13. Age-related Macular Degeneration Product Profiles
14. Age-related Macular Degeneration Companies
15. Age-related Macular Degeneration Drugs
16. Dormant and Discontinued Products
17. Age-related Macular Degeneration Unmet Needs
18. Age-related Macular Degeneration Future Perspectives
19. Age-related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-related Macular Degeneration (AMD) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Opthea, Kodiak Sciences, Regenxbio, Alexion, AstraZeneca, Allegro, Apellis, Iveric Bio here
News-ID: 3319882 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit …
How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
